GO:0102142 dermatan 2-sulfotransferase activity

Dermatan 2-sulfotransferase activity (GO:0102142) is a molecular function that catalyzes the transfer of a sulfate group from 3'-phosphoadenylyl-sulfate (PAPS) to the C2 hydroxyl of alpha-L-iduronic acid residues within dermatan sulfate chains, yielding 2-O-sulfo-alpha-L-iduronate, adenosine 3',5'-bisphosphate, and a proton. This modification is a late step in glycosaminoglycan maturation and directly determines the charge density and conformational flexibility of dermatan sulfate, which in turn affects interactions with growth factors, cytokines, and extracellular matrix proteins. The activity was first assigned to a human uronyl 2-sulfotransferase (UST) that acts on both iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. For researchers, GO:0102142 provides a precise functional annotation for experiments that measure sulfotransferase activity, map substrate specificity, or interpret proteoglycan remodeling in disease. Because sulfation patterns are not template-encoded, they must be studied enzymatically and structurally; the availability of purified enzymes and defined acceptor substrates has made it possible to determine substrate specificity of sulfotransferases and glycosyltransferases involved in proteoglycan biosynthesis. Understanding dermatan 2-sulfotransferase activity is therefore central to connective tissue biology, cancer matrix remodeling, and the development of therapeutics that target glycosaminoglycan-protein interactions. The sections below summarize the definition, mechanism, key genes, disease links, and experimental strategies for studying this activity.

GO:0102142 describes the catalysis of the reaction: dermatan-[core protein] + 3'-phosphoadenylyl-sulfate = [dermatan-sulfate] containing 2-O-sulfo-alpha-L-iduronate + adenosine 3',5'-bisphosphate + H+. In other words, the enzyme transfers a sulfate group from the universal sulfate donor PAPS onto the C2 position of iduronic acid residues that are already part of a dermatan sulfate chain attached to a core protein. The product is a dermatan sulfate chain bearing 2-O-sulfo-alpha-L-iduronate, a modification that increases negative charge and alters the chain's interaction properties. The synonym [dermatan sulfate]-L-iduronyl 2-O-sulfotransferase activity reflects this iduronyl-specific transfer.

Dermatan 2-sulfotransferase activity is important because it installs a specific sulfate mark that governs the physicochemical and biological properties of dermatan sulfate proteoglycans. This modification affects the ability of dermatan sulfate to bind growth factors, modulate coagulation, and organize extracellular matrix, and its dysregulation has been implicated in matrix-related pathologies. Because the enzyme acts on both iduronyl and glucuronyl residues, it also contributes to the structural diversity of chondroitin/dermatan sulfate chains, which is critical for tissue-specific functions. Studying this activity helps explain how cells build and remodel their glycosaminoglycan environment and provides a target for interventions in fibrosis, cancer, and connective tissue disease.

The genes and proteins most directly associated with dermatan 2-sulfotransferase activity include the uronyl 2-sulfotransferase enzyme and related sulfotransferases and glycosyltransferases that determine dermatan/chondroitin sulfate structure.

Dermatan 2-sulfotransferase activity is regulated at multiple levels. The enzyme requires PAPS, so its activity is coupled to sulfate uptake and PAPS synthesis via PAPSS1/PAPSS2 and SLC26A2. The availability of iduronyl-containing acceptor chains depends on dermatan sulfate epimerases (DSE, DSEL) and on the glycosyltransferases that assemble the proteoglycan linker and polymerize the chain. Substrate specificity studies indicate that the enzyme can act on both iduronyl and glucuronyl residues, so the composition of the acceptor chain modulates its effective activity. Assays with defined substrates are necessary to distinguish this activity from other sulfotransferases and to quantify regulation.

Altered dermatan sulfate sulfation can affect extracellular matrix assembly and has been linked to connective tissue phenotypes. The human uronyl 2-sulfotransferase that carries out GO:0102142 modifies dermatan/chondroitin sulfate chains, and changes in this modification may contribute to matrix fragility or altered growth factor sequestration. Related sulfotransferases such as CHST14 are known to be involved in dermatan sulfate biosynthesis, providing a comparative framework for disease gene discovery.

Dermatan sulfate proteoglycans are components of the tumor microenvironment, and their sulfation patterns influence growth factor binding and cell signaling. Because 2-O-sulfation changes the charge and conformation of dermatan sulfate, dysregulated activity of the enzyme could alter matrix-driven signaling in cancer. Experimental models that manipulate UST expression can test whether this activity causally affects tumor cell behavior.

Dermatan sulfate participates in inflammatory and fibrotic processes through interactions with cytokines and matrix proteins. The 2-O-sulfate mark installed by GO:0102142 can modulate these interactions, making the enzyme a potential node for studying fibrosis. Comparative analysis with other sulfotransferases helps define which effects are specific to 2-O-sulfation.

Direct measurement of dermatan 2-sulfotransferase activity uses purified enzyme or cell lysates incubated with PAPS and defined oligosaccharide acceptors, followed by detection of sulfated products. These assays are the gold standard for assigning GO:0102142 and for determining substrate specificity.

Disaccharide analysis of dermatan/chondroitin sulfate chains by chromatography or mass spectrometry can quantify 2-O-sulfo-alpha-L-iduronate and reveal changes in sulfation patterns after genetic manipulation. This approach links enzyme activity to the composition of mature proteoglycans.

Knockout, point-mutation, knock-in, and overexpression models allow causal testing of UST and related genes in cells and animals. These models can be combined with enzymatic assays and glycan profiling to connect genotype to sulfation phenotype.

RNA-seq, qPCR, and tagged knock-in approaches can measure UST expression and subcellular localization, helping to define where 2-O-sulfation occurs within the secretory pathway. Such studies complement activity measurements and provide context for regulation.

Researchers studying dermatan 2-sulfotransferase activity-related genes often need to determine whether a candidate gene is causally involved in sulfation, matrix assembly, or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services that enable precise, reproducible interrogation of these questions.

GO:0102142 dermatan 2-sulfotransferase activity defines a specific enzymatic step that installs 2-O-sulfate on iduronyl residues of dermatan sulfate, shaping the structure and function of proteoglycans in the extracellular matrix. The human UST enzyme is the founding catalyst for this activity, and its substrate specificity has been characterized using defined assays. Understanding this activity is important for connective tissue biology, cancer matrix remodeling, and inflammation, and CRISPR-based models provide powerful tools to test causal roles of UST and related genes. Continued research using enzymatic, glycomic, and genetic approaches will clarify how 2-O-sulfation contributes to health and disease.